Signature 3 (BRCA signature), associated with inactivating BRCA1 or BRCA2 mutations in breast and pancreatic cancers and prevalent in ovarian cancer [35], is present in 27/39 samples. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.